Technical Analysis for NWBO - Northwest Bioth Cmn

Grade Last Price % Change Price Change
D 0.794 0.51% 0.0040
NWBO closed down 1.25 percent on Thursday, December 2, 2021, on 75 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical NWBO trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.51%
Calm After Storm Range Contraction 0.51%
Narrow Range Bar Range Contraction 0.51%
NR7 Range Contraction 0.51%
Wide Bands Range Expansion 0.51%
Down 3 Days in a Row Weakness 0.51%
Wide Bands Range Expansion -0.75%
Calm After Storm Range Contraction -6.59%
NR7 Range Contraction -6.59%
Inside Day Range Contraction -6.59%
Older End-of-Day Signals for NWBO ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Rose Above Previous Day's High about 8 hours ago
Outside Day about 8 hours ago
Down 3% about 8 hours ago
Up 5% about 8 hours ago
Up 3% about 8 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Northwest Bioth Cmn Description

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company's lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company's platform technology, DCVax, uses activated dendritic cells to mobilize a patient's own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Health Biotechnology Cancer Clinical Medicine Immune System Nose Solid Tumors Antibodies Cancer Immunotherapy Immunotherapy T Cell Platform Technology Therapy Products Tumors Virotherapy Immunotherapy Product Immunotherapy Products Natural Killer Cell Northwest Biotherapeutics Attack Cancer Solid Tumor Cancers Tumor Antigen Vaccine

Is NWBO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.15
52 Week Low 0.7277
Average Volume 2,186,438
200-Day Moving Average 1.3400
50-Day Moving Average 1.1065
20-Day Moving Average 0.9692
10-Day Moving Average 0.8703
Average True Range 0.0931
ADX 25.69
+DI 19.2086
-DI 31.0022
Chandelier Exit (Long, 3 ATRs) 0.9507
Chandelier Exit (Short, 3 ATRs) 1.0070
Upper Bollinger Bands 1.1974
Lower Bollinger Band 0.7410
Percent B (%b) 0.11
BandWidth 47.0904
MACD Line -0.0865
MACD Signal Line -0.0731
MACD Histogram -0.0134
Fundamentals Value
Market Cap 577.88 Million
Num Shares 731 Million
EPS 0.01
Price-to-Earnings (P/E) Ratio 131.67
Price-to-Sales 378.14
Price-to-Book 0.00
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.8350
Resistance 3 (R3) 0.8367 0.8233 0.8275
Resistance 2 (R2) 0.8233 0.8119 0.8225 0.8250
Resistance 1 (R1) 0.8067 0.8048 0.8000 0.8050 0.8225
Pivot Point 0.7933 0.7933 0.7900 0.7925 0.7933
Support 1 (S1) 0.7767 0.7819 0.7700 0.7750 0.7575
Support 2 (S2) 0.7633 0.7748 0.7625 0.7550
Support 3 (S3) 0.7467 0.7633 0.7525
Support 4 (S4) 0.7450